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Abstract
Major vaccine safety controversies have arisen in several countries beginning in the last decades 
of 20th Century. Such periodic vaccine safety controversies are unlikely to go away in the near 
future as more national immunization programs mature with near elimination of target vaccine-
preventable diseases that result in relative greater prominence of adverse events following 
immunizations, both true reactions and temporally coincidental events. There are several ways in 
which vaccine safety capacity can be improved in the future to potentially mitigate the impact of 
future vaccine safety controversies. This paper aims to take a “lifecycle” approach, examining 
some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed 
(specifically U.S. and Europe) and low- and middle- income countries.
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Introduction
As we approach halfway through the Decade of Vaccines (1), the US faced its largest 
measles outbreak since the disease was “eliminated” in 2000. (2) This outbreak occurred 
mostly among unvaccinated children, some of whose parents' decision to avoid vaccination 
may have been influenced by earlier (subsequently disproven and retracted) hypothesized 
safety concerns about linkage between vaccination and autism, (3-6) and who may be 
clustered geographically. (7) The resurgence of this vaccine-preventable disease (VPD) is 
but the latest unfortunate impact of vaccine safety controversies that have arisen in several 
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countries beginning in the last decades of 20th Century (8-11). While the specific 
circumstances of each occurrence may be unique, the convergence of multiple larger forces 
may also play a role (Table 1) (12). Such periodic vaccine safety controversies are unlikely 
to go away in the near future as those factors are unlikely to change. Nevertheless, there are 
several ways in which vaccine safety capacity can be improved in the future to potentially 
mitigate the odds and impact of future vaccine safety controversies. This paper aims to take 
a “lifecycle” approach (13), examining some potential pre- and post-licensure opportunities 
to improve vaccine safety, in both developed and low- and middle- income countries 
(LMIC).
1. History of vaccine safety
Before we peer into the future, however, it is instructive to review the history [Table 2] and 
relative prominence of vaccine safety through the lens of evolution of immunization 
programs (Figure 1) (14). For most national immunization programs (NIP) and most VPD 
they target, the vast majority of the time since inception has been spent in Stage 1 (pre-
vaccine introduction) or Phase 2 (increasing vaccine coverage); phases where the number of 
VPD vastly exceed that of adverse events following immunizations (AEFI; both true vaccine 
reactions and temporally coincidental events). As sustained high vaccine coverage with an 
effective vaccine nearly eliminates a target VPD, however, the number of serious AEFI may 
gain in prominence relative to the VPD with several possible outcomes. Routine smallpox 
vaccination was discontinued (beginning with the USA and UK in 1971 before global 
eradication in 1979) when the risk of AEFI outweighed that from imported smallpox (15, 
16); stopping the use of a vaccine eradicates its AEFI (Figure 1 Phase 5). A similar rationale 
underlies the switch from live oral to inactivated polio vaccine in the USA (17) and 
elsewhere (18) when the risk of vaccine-derived paralytic polio exceeded that from wild 
polio.
A different outcome occurred for pertussis, however. Beginning in the 1970's for countries 
such as Sweden, Japan, and U.K., the success of whole cell pertussis (wP) vaccination in 
near elimination of pertussis resulted in increased attention on the high rate of wP-associated 
AEFI (fever and neurologic events), media attention, loss of confidence in wP with major 
drop in vaccine coverage, and resurgence of pertussis (Figure 1 Phase 3) (8). In the US, 
similar forces resulted instead in an increase in lawsuits and price of vaccine, loss of vaccine 
manufacturers, and eventual passage of the National Childhood Vaccine Injury Act 
(NCVIA) in 1986. (19) The development and adoption of safer (though in retrospect, also 
likely shorter duration of effectiveness (20)) acellular pertussis (aP) vaccines resulted in 
resumption of confidence with continued high vaccine coverage and control of pertussis 
(Figure 1, Stage 4).
The need to meet NCVIA's mandates for better scientific evidence for decision making on 
vaccine injury compensation helped to spur the development of several key vaccine safety 
capacity and infrastructure in the U.S. in the 1990's (Table 2). As NIPs mature globally, they 
are or will face similar challenges and needs for better vaccine safety data in their 
populations; therefore, efforts to establish similar vaccine safety capacity in other developed 
and, as described below, increasingly LMIC has begun.
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Looking ahead, since few VPD are eradicable 1 (21), most NIP will continue to confront a 
challenging (and unstable) situation of relatively high AEFI vs. VPD (pre-Stage 3). One 
possible “stabilizing” solution is to harness the scientific data inherent in AEFI to potentially 
immunize safer by identifying new contraindications or develop safer vaccines. 
Distinguishing a true vaccine reaction from all the coincidental AEFI, (22) let alone 
understanding the pathogenesis has always been challenging. This paper lays out some steps 
to fulfilling the potential for improving the science of vaccine safety in an era of large 
datasets, genomics, personalized medicine, and multi-national collaborative studies, and 
thereby enhance the sustainability of successful NIP.
2. Opportunities to enhance vaccine safety in regulatory setting
Starting with the Biologics Control Act of 1902 in the U.S. (in response to 13 deaths in 
recipients of tetanus-contaminated diphtheria antitoxin) (23), many of the lessons learnt 
from vaccine safety crises subsequently have been codified by national regulatory 
authorities (NRA) [or the World Health Organizations (WHO) for the countries without 
NRAs] for the licensure and procurement of safe and effective vaccines of high quality (24). 
The continued evolution and modernization of these regulations (or guidance documents) for 
new biotechnologies used in vaccine development and production are crucial to preventing 
future vaccine safety problems (25). For example, the US Food and Drug Administration 
(FDA) just issued a draft guidance on Current Good Manufacturing Practice Requirements 
for Combination Products such as a vaccine in a micro-needle device (26). The European 
Medicines Agency issued its guidelines on live recombinant viral vectored vaccines in 2011 
applicable to several Ebola vaccine candidates (27). The WHO issued its guidance on 
regulatory risk evaluation on finding an adventitious agent in a marketed vaccine in 2014 
(28). Additional opportunities for enhancing regulatory science have recently been 
summarized (29, 30).
More challenging are the tasks facing NRAs in LMIC's. Many are relatively newly 
established and may have limited experience and/or expertise, especially in highly 
subspecialized biotechnologies (24, 25). Once pre-qualified by WHO, manufacturers in 
these countries are now providing much of the vaccines used globally (31). The NRA's 
providing oversight over these manufacturers may need technical assistance to ensure these 
vaccines meet good manufacturing practice and other global standards. Groups such as the 
Developing Country Vaccine Regulators Network (DCVRN) and African Vaccine 
Regulatory Forum (AVAREF) may help bridge some of the identified gaps (32).
3. Opportunities to enhance the evaluation of vaccine safety in pre-
licensure setting
Recent efforts have helped improve the evaluation of vaccine safety in the prelicensure 
setting. Better standardization and use of case definitions for AEFIs (e.g., as organized via 
the Brighton Collaboration) and toxicity grading scales allow greater accuracy and 
1Even the few VPD that are eradicable, it may be unwise to stop these immunizations in an era of bioterrorism and recreate conditions 
similar to the devastations wreaked by the introduction of diseases like measles and smallpox into various isolated populations by 
great explorers beginning in the 16th Century.
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comparability needed for scientifically rigorous studies of vaccine safety (33). The Brighton 
Collaboration has also developed guidelines for standardized assessment of the safety 
elements in protocols of clinical trials investigating vaccines (34). For viral vector vaccines, 
a working group has been formed to anticipate and standardize assessment of potential 
safety issues, thereby facilitating their eventual public acceptance when licensed (35). 
Sponsors of new candidate viral vector vaccines can facilitate transparent discourse among 
key stakeholders by completing its standardized template with key considerations for risk/
benefit assessment (36).
Data Safety Monitoring Boards (DSMB) can be improved by ensuring they include persons 
with safety (i.e., pharmacovigilance and pharmacoepidemiology - not just infectious disease 
epidemiology) skills. The cumulative safety experience of a new candidate vaccine from all 
trials should be available to the DSMB, not just the limited experience from the current trial 
underway (37). In addition to the principal investigator making an assessment of the 
possible causal relationship between a candidate vaccine and an AEFI, clinical trials could 
be organized within healthcare organizations that maintain large linked databases. This 
would potentially allow seamless capture of safety data from trial subjects over longer 
periods as well as combined analyses with evolving postmarketing data (38).
4. The future of post-licensure vaccine safety: United States perspective
The United States has a well-developed post-licensure vaccine safety monitoring 
infrastructure that largely resides in the US Department of Health and Human Services, 
which includes passive surveillance through the Vaccine Adverse Event Reporting System 
(VAERS) (14), active surveillance using large-linked electronic health record databases in 
the Vaccine Safety Datalink (VSD) (39) and the Postlicensure Rapid Immunization Safety 
Monitoring (PRISM) systems (40) and clinical research activities through the Clinical 
Immunization Safety Assessment (CISA) Project (41). Vaccine manufacturers might also 
conduct post-licensure safety studies as part of postmarketing requirements or commitments 
in accordance with Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (42). The 
Centers for Disease Control and Prevention (CDC) and the US Food and Drug 
Administration (FDA) are responsible for post-licensure monitoring of vaccines and CDC 
and FDA systems provide the foundation for safety surveillance in the United States. Post-
licensure safety data are routinely presented to CDC's Advisory Committee on 
Immunization Practices (ACIP) (43) and FDA's Vaccines and Related Biological Products 
Advisory Committee (VRBPAC) (44) and Pediatric Advisory Committee (45) for 
consideration during policy deliberations and in the context of regulatory decision making.
Advances in information technology and biomedical science, modifications and expansion 
to the US immunization program, and evolving parent and patient safety concerns 
necessitate that CDC and FDA rapidly adapt to the changing public health and regulatory 
environments. Selected examples of anticipated future issues as well as current and planned 
vaccine safety initiatives are described below.
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4.1 Harnessing new information technology
An important opportunity for public health surveillance in the information age is to take full 
advantage of advances in modern technology (46). These advances facilitate information 
capture through enhanced reporting, information linkage, and improved pattern recognition. 
When put into full production, the technological enhancements described here have the 
potential to substantially improve the efficiency, timeliness and quality of vaccine safety 
surveillance.
Despite the proliferation of electronic healthcare data, lags in data processing ensure that 
VAERS remains the fastest link between an astute observer of a sentinel AEFI and public 
health and regulatory authorities. Thus, VAERS has added importance in the first few weeks 
of a situation such as an influenza pandemic when large numbers of persons may be 
immunized over a short time. Currently underway is a joint CDC-FDA initiative to 
transform VAERS from a legacy paper-based system into a modern information system that 
maximizes online reporting capability (47, 48) and electronic data interchange (49, 50). In a 
separate initiative, CDC is investigating the utility and feasibility of incorporating 
specialized computer algorithms into electronic health records to facilitate physician 
identification and reporting of adverse events to VAERS directly from electronic health 
record systems using standardized electronic messages – a form of enhanced passive 
surveillance (51, 52). Additionally, exploratory work using mobile technologies like 
handheld devices and smart phones to facilitate vaccine safety surveillance and research has 
shown promise (53, 54).
Another important technological advance is statistical techniques using complex software 
programs that allow large volumes of data to be rapidly analyzed to identify unusual and 
unexpected patterns. Empirical Bayesian data mining to detect disproportional reporting has 
already been incorporated into routine VAERS surveillance (55-57) and natural language 
processing (58) and text mining (59) hold early promise for rapid case classification in both 
active and passive surveillance. In the VSD system, rapid cycle sequential analytic methods 
have been developed to conduct near real-time (weekly) monitoring for pre-specified 
conditions following individual vaccines and types of vaccine (39, 60-62). As part of the 
process, advanced statistical techniques have been developed and are routinely used to 
monitor influenza vaccine safety during each influenza season and to monitor newly 
recommended vaccines during the uptake period (63-65). Rapid cycle analysis was 
particularly valuable in monitoring the safety of 2009 influenza A (H1N1) monovalent 
vaccine during the large-scale pandemic influenza vaccination program in the Unites States 
(66). Within the PRISM system, a new effort is underway to detect AEFI of potential 
concern without pre-specification (67). PRISM health outcome data can be hierarchically 
organized using the Agency for Healthcare Research and Quality's Multi-Level Clinical 
Classification software (68) and TreeScan is a statistical method that can be used to analyze 
such data (69). The PRISM pilot improves upon the underlying statistical method (70) 
through the use of unconditional and conditional variants of a self-controlled tree-temporal 
scan statistic. If successful, this method will enable population-based safety signal 
identification. This would represent a significant new capability since to date PRISM has 
primarily been used for signal strengthening and validation. All of these technological 
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improvements will continue to require experienced pharmacovigilance and 
pharmacoepidemiology staff who can critically review pattern recognition output within 
relevant medical and public health context.
4.2 Vaccination in pregnancy
Vaccination in pregnancy is unique in that the benefits might potentially extend to the 
pregnant woman and the developing fetus, as well as to the newborn infant as a result of 
antibody transfer (71). Pregnancy is typically an exclusion criterion for pre-licensure clinical 
trials, so intensive safety monitoring is critical following recommendations to vaccinate 
during pregnancy. Currently in the United States, only two vaccines are routinely 
recommended for all pregnant women, inactivated influenza and combined tetanus, 
diphtheria and pertussis (Tdap) vaccines (72, 73). Although ACIP has considered available 
scientific evidence prior to making recommendations, (74-76) data on the safety of 
vaccination in the early stages of pregnancy or just prior to conception, and for repeat 
vaccination at short intervals – as in the case of the Tdap recommendation – are limited. 
Safety monitoring is becoming increasingly important as uptake of these vaccines in 
pregnancy increases and investigational vaccines for use in pregnancy, such as group B 
streptococcus and respiratory syncytial virus vaccines, are developed (77, 78). FDA's new 
Pregnancy and Lactation Labeling Rule, effective June 30, 2015, enhances the level of detail 
communicated within Pregnancy, Lactation, and new Females and Males of Reproductive 
Potential sections of the package insert (79). The agency expects that including information 
derived from scientifically acceptable pregnancy exposure registries in prescription drug and 
vaccine labeling may encourage additional data collection (80). Effective use of surveillance 
systems that rely on large linked electronic health record databases that enable rapid 
comparisons and estimates of risk of adverse pregnancy outcomes will be critical to building 
and maintaining confidence in expanded maternal vaccination programs moving forward.
4.3 Complex safety issues beyond single vaccines
In 2013 the Institute of Medicine (IOM) issued a report on the safety of the childhood 
immunization schedule (81). The IOM did not find any evidence to suggest that the 
immunization schedule was not safe; however, there was acknowledgement that limited 
evidence was available on the safety of the immunization schedule as a whole and parents 
and other stakeholders viewed this as an important concern. Additionally, the IOM 
concluded that using randomized clinical trials or prospective cohort studies to address this 
issue would be unethical or not feasible. In its report, the IOM identified CDC's VSD as the 
best surveillance system to conduct research to evaluate the safety of the immunization 
schedule. Given the challenges of evaluating the safety of the immunization schedule in a 
highly vaccinated population (82) and differences in healthcare utilization based on 
vaccination status (83), developing and exploring the use of new and innovative 
methodologies will be critical, particularly for studying rare outcomes with potentially long 
time periods between exposure and onset.
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4.4 New manufacturing technologies and delivery systems
We are living in an era of rapid advances in biotechnology and biomedical science. DNA 
vaccines, recombinant vector vaccines and other novel types of vaccines, adjuvants and 
delivery systems are in various stages of development and testing (84-88). Although these 
new types of vaccines and delivery systems have great potential, there is not an existing 
body of knowledge on their general safety as there is for the older, more conventional 
vaccine products currently in use. Appropriate monitoring and post-marketing safety studies 
will be necessary to ensure the safety of new vaccines. Monitoring for rare adverse events 
that may not have been identified in pre-licensure clinical trials will be particularly 
important to guide appropriate public health action to ensure safety, if necessary.
4.5 Systems biology and personalized medicine
Systems biology involves incorporating elements from the fields of cell biology, proteomics, 
genomics, immunology, computational modeling and others to “… understand functioning 
at the level of the organism, tissue, or cell” (89). By contrast, personalized or precision 
medicine “… uses an individual's genetic profile to guide decisions made in regard to the 
prevention, diagnosis, and treatment of disease” (90). In the context of vaccine safety, 
applying knowledge gained from basic science, clinical research and systems biology to 
direct patient care might eventually lead to routine screening tests or other procedures that 
guide healthcare providers' vaccination decisions in order to maximize benefit and minimize 
adverse reactions at the individual patient level. The logical extension is to harness systems 
biology and genetic research to guide vaccine development, possibly even the development 
of personalized vaccines for individual patients based on a unique genetic profile (91-93). 
Although these concepts might seem futuristic, it is interesting to note that advancing 
precision medicine was highlighted in President Barack Obama's 2015 State of the Union 
Address (94). There is reason to be optimistic that the field of vaccinology could benefit 
from a concerted focus on systems biology research, which in turn could be applied to 
personalized medicine.
5. European Perspective
In the European Union (EU), new vaccines are introduced according to centralized 
regulatory procedures, which implies that they are licensed with common indications for 
their use across member countries. Although many countries use similar immunization 
schedules and may also use the same commercial products, they may concurrently 
administer different vaccines, measure vaccine coverage in different ways or in different age 
groups and have different systems for monitoring adverse events (95).
Several countries in the EU, such as United Kingdom, Denmark, Sweden, Finland, Germany 
and the Netherlands have well established academic and/or public health capacity for active 
surveillance of vaccine safety and each single country contributes significantly to science, 
regulatory and public health issues. However, approaches tended to be based on national 
data only, were highly variable across member states, and dependent on national budgets. To 
help address this fragmentation, the European Center of Disease Control and Prevention 
(ECDC) funded the VAESCO II project (Vaccine Adverse Event Surveillance and 
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Communication project) (95). VAESCO attempted to translate the experience of the VSD 
Project in the United States to the European context. It also capitalized on the landmark EU-
Adverse Drug Reaction (ADR) system, which was started to improve the scale and level of 
drug safety surveillance assessments for small molecules by pooling databases across 
European national jurisdictions (96).
The safety of the 2009 H1N1 pandemic influenza vaccine was assessed in an unprecedented 
fashion in the EU for VAESCO by federating a variety of health care databases. As a result, 
the background rates of 12 adverse events of interest were assessed in eight countries in four 
months. Case control studies and self-controlled case series analyses on the association 
between the pandemic influenza vaccine and Guillain-Barré syndrome were conducted with 
data from seven countries. Consequently, expert committees at the European Medicines 
Agency (EMA) were able to be informed on a timely basis (97-100). The association 
between pandemic influenza vaccine and narcolepsy was assessed by changes in population-
based incidence rates and case control studies using data from eight countries (98, 99). All 
studies were designed to enable pooling of individual-level patient data. They also used a 
common protocol, standardized methods, shared information technology infrastructure for 
international data transfer (in line with the European data protection directive), and a central 
data management and analysis team.
Lessons learned from the VAESCO experience identified five main issues as critical to the 
future development of a successful European collaboration in vaccine safety monitoring and 
research: sustainability, governance, purpose, structure, and ethical and administrative 
approvals (95). The VAESCO project ended in 2012 while the narcolepsy signal was still 
incompletely evaluated; this was due to resource constraints at ECDC, which was funded 
through the European Commission. This experience highlights the need for long-term 
commitment and sustainability planning if countries are to perform ongoing, coordinated 
signal assessment and state of the art research. Another lesson around safety monitoring of 
pandemic influenza vaccine in Europe underscored a need to allow for transparent 
interaction between public (e.g. public health organizations), and private (e.g., vaccine 
manufacturers) stakeholders. The existing governance at the time did not allow the vaccine 
manufacturer to participate in the research, thereby compelling the manufacturer to conduct 
its own research in Canada in order to comply with European regulatory obligations.
To help address this issue, the Innovative Medicines Initiative (IMI) in 2012 called for a 
public-private partnership on development of a framework for rapid monitoring of vaccine 
benefits and risk. Consequently, the Accelerated Development of VAccine beNefit-risk 
Collaboration in Europe (ADVANCE; www.advance-vaccines.eu) consortium was formed 
in October 2013 for five years. The ADVANCE framework is being developed for wide 
adoption and implementation by all stakeholders, including ECDC, national public health 
bodies, the EMA, national regulatory agencies, health ministries, insurance companies, 
vaccine manufacturers, healthcare providers, and the general public. Bringing together these 
diverse groups is challenging. But doing so around a neutral platform offered by IMI will 
allow ADVANCE to develop a blueprint for a sustainable and rapid system to monitor 
benefits and risks of vaccines in Europe.
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In summary, the active surveillance programs to monitor the safety of the 2009 pandemic 
H1N1 influenza vaccines (requested by ECDC, EMA, academics and national public health 
institutes) changed the paradigm in Europe in terms of innovation, research scale, size of 
population monitored, degree of collaboration, standardization of methods, and 
sophistication of shared research infrastructures. Looking ahead, these programs could 
leverage the infrastructures and methods for distributed networks and methods that have also 
been built in Europe to address similar needs to improve drug safety methods and 
collaborations (96).
6. Monitoring vaccine safety in low- and middle-income countries (LMIC)
The Expanded Programme on Immunization (EPI) launched in 1974 has transformed 
vaccination coverage in LMIC (101). Through a systematic effort based on tailored 
strategies and implementation of adaptive vaccine delivery tools, EPI has made it possible to 
reach children in the most remote parts of the world. This success required addressing 
complex supply chain issues, while managing procurement, negotiating costs, and 
establishing effective information systems. As a result, millions of untimely deaths are now 
prevented every year. At the turn of the 21st century, EPI expanded the range of VPD by 
introducing new vaccines in LMIC (102). An increasing number of vaccine products are 
now available, some developed primarily for use in LMIC and several available from 
manufacturers (103).
6.1 Passive surveillance of AEFI
Not surprisingly, the “maturation” of EPIs in LMICs with better VPD control is also 
resulting in increased attention on possible AEFI's (14). These concerns require adequate 
and timely evidence to help NIP managers address those risks, propose sound responses to 
decision-makers, and maintain communities' trust in immunization services (104).
In 2012, WHO and its partners developed a strategy to help LMIC establish and strengthen 
their vaccine safety monitoring systems. The Global Vaccine Safety Blueprint (GVSB) 
(105) proposes three strategic goals: 1) establish minimal vaccine safety capacity in all 
countries; 2) provide enhanced capacity when vaccines are manufactured in-country, or 
products are introduced in populations; and 3) provide a technical support network. GVSB 
implementation is ensured by a network of technical partners that participate in the Global 
Vaccine Safety Initiative (GVSI) (106), which offers a common platform to partners 
interested in furthering vaccine safety systems. It align their activities (107) and compiles 
them in a portfolio (108).
Currently, a majority of LMIC do not have the elements of minimal vaccine safety capacity 
in place as reflected by the very low number of AEFI reported annually (109). However, 
several countries have recently made remarkable progress through the application of a five-
step capacity-building model of benchmarking, assessment, planning, implementation, and 
monitoring (110). In addition, the introduction of new vaccines presents opportunities for 
conducting enhanced AEFI monitoring, as was the case with meningococcal A conjugate 
vaccine in sub-Saharan Africa (111). The eventual availability of more complex products, 
such as an adjuvanted malaria (112) vaccine or viral vectors that express dengue (113) or 
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Ebola virus (114) antigens, will require additional scrutiny in the post-clinical stages. Early 
planning for such scenarios which engages a broad array of stakeholders is underway 
through the Council for International Organizations of Medical Sciences Vaccine Safety 
Working Group (115). Full-scale introduction of these vaccines will undoubtedly provide 
opportunities for furthering the GVSI and help garner the political support required to 
implement its strategies.
6.2 Active surveillance of AEFI
As noted above, several new vaccines targeting infectious tropical and subtropical diseases 
(e.g., dengue) are in advanced stages and may be licensed in the near future. These vaccines 
have the potential to be widely used (116) since most children live in LMIC and 
immunizations are among the most effective health interventions. Many of these new 
vaccines may also be introduced, possibly exclusively, in LMIC where capacity for program 
evaluation and safety monitoring post-licensure has been relatively weak -- without similar 
data from high resource countries (117). While passive surveillance is important to generate 
and detect new safety signals, active surveillance systems need to be developed and 
maintained to better quantify risk associations between an administrated vaccine and a 
potential AEFI.
Ideally and in a long-term perspective, active surveillance systems for vaccine safety 
monitoring should be well integrated in national health systems. Initially, the focus might be 
building on existing infrastructure and capacity so that it can reliably identify AEFIs. 
Therefore, the identification and evaluation of existing longitudinal demographic, health and 
vaccination program information and data collection systems (e.g., birth cohorts, morbidity 
surveillance, and vaccination registries) are crucial. The utility of these systems for vaccine 
safety assessment purposes can be evaluated by trying to replicate already known positive 
adverse event associations (e.g., febrile seizures following measles vaccination).
The results of such evaluations can inform the investments needed to adapt existing 
infrastructures and capacity for an integrated active vaccine safety surveillance system. 
These investments need to target: 1) demographic surveillance systems (i.e., to generate 
reliable population denominator, socioeconomic data), 2) morbidity and health outcome 
registries (i.e., to collect potential AEFI and monitor incidence rates of events of interest in 
vaccinated and unvaccinated persons), and 3) vaccination registries (i.e., to relate potential 
adverse events to exposure and to monitor vaccination administration). All three information 
categories need to be linked with a unique identifier and integrated in an active vaccine 
safety surveillance system.
On a regional level, the International Network for the Demographic Evaluation of 
Populations and Their Health (INDEPTH) member centers (118) are examples of 
infrastructure where an active vaccine safety system could be integrated. The centers have 
extensive experience with epidemiologic studies. Many INDEPTH centers are already 
collecting, managing, and analyzing linkable household individual and clinic-based health 
and demographic surveillance system (HDSS) data. Several centers are also collecting 
vaccine exposure information and are located in south Asia and Africa where new vaccines 
are likely to be introduced. The coverage and longevity of INDEPTH would facilitate 
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monitoring and assessment of rare safety concerns requiring large populations with enough 
follow-up person-time. Alternatively, population-based surveillance monitoring for potential 
AEFI requiring hospitalization could also be established (119).
The establishment and sustainability of active vaccine safety surveillance systems in LMIC 
will need substantial investments in linkable demographic, heath outcome, and vaccination 
administration information systems. Hopefully the key stakeholders (e.g., national public 
health and regulatory institutions, academia, industry, WHO, and private donors investing in 
the development and administration of vaccines) will help bring this vision into reality 
(120).
7. Conclusion
Among various promethean human endeavors, immunizations are remarkable for their aim 
to alter the ecologic relationship between Homo sapiens and the targeted infectious disease 
species in human's favor. We are in a unique moment in the history of Homo sapiens as the 
species attempt to shift from wild VPD-induced immunity (with high price paid in morbidity 
and mortality) historically to vaccine-induced immunity prospectively. The formidable task 
of building the infrastructure needed for sustainable maintenance of vaccine-induced 
immunity for each successive birth cohort globally has just begun. Such an infrastructure 
should include robust vaccine safety systems needed to timely detect, assess and if needed, 
minimize the risks of immunizations. Several key elements of the vaccine safety system are 
in place in some developed countries. Hopefully with adequate resource investment, they 
can serve as the foundations of an eventual global system as the remaining countries 
(including many LMIC's) build theirs as biotechnology continues to bring new vaccines 
from dream to reality.(84, 121, 122)
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Potential stages in the evolution of immunization program, showing the dynamics of the 
interaction between vaccine coverage, disease incidence and vaccine adverse events, as the 
program matures from pre-vaccine to disease eradication.(14)
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Table 1
Some factors whose recent convergence may increase the risk of vaccine safety 
controversies (12, 123, 124)
1) Lower tolerance for immunization risks: Medical intervention, including immunizations, aims to minimize the risks while maximizing the 
benefits. Because most immunizations are administered to healthy persons (frequently babies) to prevent illness, are commonly recommended 
for near-universal use, and are often legally required for school entry, the tolerance for risks is much lower than most other medical 
interventions (generally targeted at treating ill patients).
2) Increasing maturity of National Immunization Programs (NIP): Most NIPs are maturing with high coverage and effectiveness of most 
commonly used immunizations, resulting in (near) elimination of their target vaccine-preventable disease (VPD) (125)but also an increased 
number of adverse events following immunizations (AEFI; both true reactions and temporally coincidental events).
3) Limited clinical trial sample size: The inherent limits of sample size in pre-licensure clinical trials usually means rare, AEFIs are likely to 
be detectable only in post-licensure settings once larger populations are immunized (126);
4) New vaccines and complex schedules: The biotechnology revolution triggered by our ability to sequence the genome of any microorganism 
has enhanced our ability to develop and introduce new vaccines (121, 122); each of whom, however, needs to be added to an already complex 
routine immunization schedule, thereby raising concerns in some parents about “over-immunization” of their babies (123). Furthermore, pre-
licensure clinical trials often involve looking at a single vaccine and comparator control vaccine or placebo, or a minimal number of 
simultaneous vaccines. This is not necessarily how vaccines are administered in children in practice, where many vaccines might be co-
administered. So the pre-licensure trials might not be representative of how vaccine is administered to children in practice and does not 
completely address the issue of simultaneous vaccination and the safety of the schedule (81).
5) Evolving Parenting: Post-modern parenting aiming to make optimal informed risk-benefit decision for their own child may overemphasize 
perceived vaccine risks in absence of wild disease, thereby delay (“hesitate”) or increase use of exemptions to mandated immunizations (123, 
124);
6) Diverging risk-benefit: For vaccines that confer herd immunity, there is an inherent divergence between societal and individual risk-benefit 
at high vaccine coverages (127);
7) Time lag between hypothesis and evidence: Hypothesis testing validation studies of rare vaccine safety associations are difficult, costly, 
time consuming, and can usually tackle only one or small number of AEFI's at a time. Even under optimal circumstance, months but typically 
years are usually needed for expert consensus to develop based on appropriately gathered scientific evidence. Therefore there is an inherent 
mismatch in timespan between the questions (and expectations) raised by rapid and unpredictable communications via 24/7 mass media and 
social network apps on cell phones and scientific process that allow vaccine safety controversies to amplify (124, 128).
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Table 2
Some highlights in the history of vaccine safety in the U.S., pre- and post- National 
Childhood Vaccine Injury Act (NCVIA) of 1986
• Pre-1986 NCVIA
– 1902 Biologics Control Act after tetanus contamination of diphtheria antitoxin and smallpox vaccine (23)
– 1942, hepatitis B contaminated yellow fever vaccine (129)
– 1955 Cutter incident (130-132)
– 1967 Publication of The Hazards of Immunization by Sir G.S. Wilson (133)
– 1976 Swine influenza vaccine and Guillain-Barre Syndrome (GBS) (134)
• Post-1986(NCVIA (134)
– Hypothesis Generation
♦ 1990: Vaccine Adverse Event Reporting System (VAERS) (14, 135); combining Monitoring System for Adverse 
Events Following Immunizations (MSAEFI) (136) and Adverse Drug Reaction (ADR) Reporting (for vaccines) 
(137)
♦ 2001: Data mining for signal detection in VAERS (138) (55-57)
♦ 2005: Using electronic medical records to enhance detection and reporting of vaccine adverse events. (51)
– Hypothesis Strengthening
♦ 2000: Brighton Collaboration standardized case definitions for AEFI's (139).
♦ 2001: Clinical Immunization Safety Assessment (CISA) Network (41)
♦ 2005: Rapid Cycle analysis using Maximized Sequential Probability Ratio Test of the Vaccine Safety Datalink 
(VSD) project (61)
– Hypothesis Testing
♦ 1989: Vaccine Safety Datalink project (140)
♦ 2009: Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program: (40)
– Risk Perception and Vaccine Acceptance/Hesitancy
♦ 1998: Lessons from risk communications (141)
♦ National Immunization Information Hotline (142)
– Institute of Medicine (IOM) reviews (81, 143-146)
– Non-US:
♦ Large Linked Databases:
• UK (147)
• Denmark (148)
– Genomic studies (149)
• Europe (95)
– Low and Middle Income Countries (LMIC)
♦ Mass campaign and AEFI surveillance
• Brazil: (150, 151)
• Burkina Faso: (152)
♦ Safe Injection Global Network (SIGN) (153)
♦ Large Linked Databases (154)
– Methods:
♦ Use of VAERS as registry of rare reactions for hypothesis testing (155)
♦ First use of self-control case series study design (147) ; first application in the VSD project (156)
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♦ Rapid Cycle analysis using Maximized Sequential Probability Ratio Test of the Vaccine Safety Datalink (VSD) 
project (39, 60-62)
♦ Distributed Data Network Model in VSD, 2001 (60)
♦ Data sharing in the VSD, 2002 (60)
♦ Genomics study (157-159)
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